GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (ASX:NAN) » Definitions » Capital Expenditure

Nanosonics (ASX:NAN) Capital Expenditure : A$-2.56 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Nanosonics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Nanosonics's cash flow for capital expenditures for the six months ended in Dec. 2023 was A$-1.1 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.56 Mil.


Nanosonics Capital Expenditure Historical Data

The historical data trend for Nanosonics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanosonics Capital Expenditure Chart

Nanosonics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.24 -1.94 -1.37 -6.97 -3.57

Nanosonics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.96 -4.01 -2.12 -1.45 -1.12

Nanosonics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-2.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanosonics (ASX:NAN) Business Description

Traded in Other Exchanges
Address
7-11 Talavera Road, Level 1 Building A, Macquarie Park, Sydney, NSW, AUS, 2113
Nanosonics is a single-product firm and its trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low temperature sonically activated hydrogen peroxide mist that is suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection across patients. Nanosonics' revenue is made up of capital sales of trophon units, ongoing consumables sales, and service revenue. At June 2022, there were 29,850 trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, roughly 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in Asia-Pacific.

Nanosonics (ASX:NAN) Headlines